Last reviewed · How we verify
Recombinant antithrombin (rhAT)
Recombinant antithrombin (rhAT) is a Dispersion agent; enzyme Small molecule drug developed by Mayo Clinic. It is currently FDA-approved for Subcutaneous Fluid Administration for Achieving Hydration, Increasing the Dispersion and Absorption of Other Injected Drugs, Improving Resorption of Radiopaque Agents in Subcutaneous Urography. Also known as: ATryn®.
Recombinant antithrombin (rhAT) is a protein-based inhibitor that targets coagulation factor X. It is being studied for various conditions, including preeclampsia, antithrombin deficiency, and thrombophilia due to acquired antithrombin III deficiency.
At a glance
| Generic name | Recombinant antithrombin (rhAT) |
|---|---|
| Also known as | ATryn® |
| Sponsor | Mayo Clinic |
| Drug class | Dispersion agent; enzyme |
| Target | Hyaluronic acid and connective tissue polysaccharides |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Subcutaneous Fluid Administration for Achieving Hydration
- Increasing the Dispersion and Absorption of Other Injected Drugs
- Improving Resorption of Radiopaque Agents in Subcutaneous Urography
Common side effects
Drug interactions
- Furosemide
- Benzodiazepines
- Phenytoin
- 2% Lidocaine with 1:100,000 or 1:200,000 Epinephrine
- Dopamine
- Alpha agonist drugs
- Local anesthetics
- Salicylates
- Cortisone
- ACTH
- Estrogens
- Antihistamines
Key clinical trials
- Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PHASE3)
- Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery (PHASE4)
- Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations. (PHASE3)
- Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant antithrombin (rhAT) CI brief — competitive landscape report
- Recombinant antithrombin (rhAT) updates RSS · CI watch RSS
- Mayo Clinic portfolio CI
Frequently asked questions about Recombinant antithrombin (rhAT)
What is Recombinant antithrombin (rhAT)?
What is Recombinant antithrombin (rhAT) used for?
Who makes Recombinant antithrombin (rhAT)?
Is Recombinant antithrombin (rhAT) also known as anything else?
What drug class is Recombinant antithrombin (rhAT) in?
What development phase is Recombinant antithrombin (rhAT) in?
What does Recombinant antithrombin (rhAT) target?
Related
- Drug class: All Dispersion agent; enzyme drugs
- Target: All drugs targeting Hyaluronic acid and connective tissue polysaccharides
- Manufacturer: Mayo Clinic — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Subcutaneous Fluid Administration for Achieving Hydration
- Indication: Drugs for Increasing the Dispersion and Absorption of Other Injected Drugs
- Indication: Drugs for Improving Resorption of Radiopaque Agents in Subcutaneous Urography
- Also known as: ATryn®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing